ストックスクリーナーアプリを入手
10.32
14.16%
1.28
アフターアワーズ：
10.20
-0.12
-1.16%
Lexaria Bioscience Corp (LEXX) 最新ニュース
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - tipranks.com
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Canada
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - tipranks.com
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com India
Lexaria Enters a Material Transfer Agreement with PegBio - TradingView
News by ACCESS Newswire on TradingView, 2026-08-13 - TradingView
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Lexaria Bioscience plans 1-for-15 reverse stock split By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp. Revenue Breakdown – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
Lexaria Bioscience Corp (LEXX) Income Statement - TradingKey
LEXX|Lexaria Bioscience Corp|Price:9.100|Chg%:+1.000 - TradingKey
LEXX|Lexaria Bioscience Corp|Price:4.495|Chg%:-0.256 - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Date & Reports & Earnings News - TradingKey
Lexaria Bioscience Corp (LEXX) Institutional Confidence - TradingKey
Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp. 10-Q Q3 2026: Financial Results, NASDAQ Listing, and Key Highlights - Minichart
Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings - Quiver Quantitative
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 - marketscreener.com
Lexaria Bioscience Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com - Investing.com Nigeria
Lexaria Updates Business Development - Investing News Network
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
LEXXLexaria Bioscience Corp Forecast, Target Price - Finviz
Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX) - TradingView
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy - citybuzz -
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts 5-week human GLP-1 study using tablet and capsule forms - Stock Titan
Lexaria Bioscience (LEXX) Advances in Animal Study #1 on Formula - GuruFocus
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts animal GLP-1 study, adds Australian patent - Stock Titan
Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp. Financial Disclosures & SEC Filings - TradingView
Lexaria Bioscience Corp (LEXXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Institutional Confidence - TradingKey
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):